Positive News SentimentPositive NewsNASDAQ:SAVA Cassava Sciences (SAVA) Stock Price, News & Analysis $2.00 -0.04 (-1.72%) As of 12:29 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About Cassava Sciences Stock (NASDAQ:SAVA) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Cassava Sciences alerts:Sign Up Key Stats Today's Range$1.96▼$2.0450-Day Range$1.19▼$2.2452-Week Range$1.15▼$42.20Volume262,188 shsAverage Volume3.00 million shsMarket Capitalization$96.86 millionP/E RatioN/ADividend YieldN/APrice Target$54.50Consensus RatingModerate Buy Company OverviewCassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2 clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. Cassava Sciences, Inc. was incorporated in 1998 and is based in Austin, Texas.Read More… Cassava Sciences Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks76th Percentile Overall ScoreSAVA MarketRank™: Cassava Sciences scored higher than 76% of companies evaluated by MarketBeat, and ranked 255th out of 933 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.3 / 5Analyst RatingModerate Buy Consensus RatingCassava Sciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 1 hold rating, and no sell ratings.Amount of Analyst CoverageCassava Sciences has only been the subject of 1 research reports in the past 90 days.Read more about Cassava Sciences' stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Cassava Sciences are expected to grow in the coming year, from ($3.97) to ($0.62) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Cassava Sciences is -1.46, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Cassava Sciences is -1.46, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCassava Sciences has a P/B Ratio of 0.62. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Cassava Sciences' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted22.91% of the float of Cassava Sciences has been sold short.Short Interest Ratio / Days to CoverCassava Sciences has a short interest ratio ("days to cover") of 6.3.Change versus previous month Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCassava Sciences does not currently pay a dividend.Dividend GrowthCassava Sciences does not have a long track record of dividend growth. Sustainability and ESG4.7 / 5Environmental Score-0.82 Percentage of Shares Shorted22.91% of the float of Cassava Sciences has been sold short.Short Interest Ratio / Days to CoverCassava Sciences has a short interest ratio ("days to cover") of 6.3.Change versus previous month News and Social Media3.3 / 5News SentimentN/A News SentimentCassava Sciences has a news sentiment score of 1.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.87 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Cassava Sciences this week, compared to 8 articles on an average week.Search Interest14 people have searched for SAVA on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Cassava Sciences to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Cassava Sciences insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 2.40% of the stock of Cassava Sciences is held by insiders.Percentage Held by InstitutionsOnly 38.05% of the stock of Cassava Sciences is held by institutions.Read more about Cassava Sciences' insider trading history. Receive SAVA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cassava Sciences and its competitors with MarketBeat's FREE daily newsletter. Email Address SAVA Stock News HeadlinesCassava Sciences Inc.May 16, 2025 | barrons.comCassava Technologies, Zindi collaborate on AI servicesMay 12, 2025 | msn.comBuffett’s Next Move Could Shock Wall StreetIn just a few weeks, a move decades in the making could be revealed — and when it is, it could ignite the next great gold rush. Savvy insiders are quietly positioning now… before Buffett makes it official. Garrett Goggin has already pinpointed four tiny-gold-miners that could 100X once the announcement hits. It’s the perfect moment to be greedy — before the herd wakes up.May 30, 2025 | Golden Portfolio (Ad)New report finds concerning levels of lead in popular cassava itemsMay 12, 2025 | yahoo.comCassava Reports Q1 2025 Financials Results, Provides Business UpdateMay 9, 2025 | finance.yahoo.comZindi Teams Up with Cassava to Spotlight African AI TalentMay 6, 2025 | msn.comZindi Supports Cassava Technologies with 85 K Zindians to showcase African AI innovationMay 5, 2025 | msn.comCassava Appoints Angélique Bordey, PhD, to Enhance Preclinical Program in TSCMay 1, 2025 | globenewswire.comSee More Headlines SAVA Stock Analysis - Frequently Asked Questions How have SAVA shares performed this year? Cassava Sciences' stock was trading at $2.36 at the beginning of the year. Since then, SAVA stock has decreased by 14.6% and is now trading at $2.0150. View the best growth stocks for 2025 here. How were Cassava Sciences' earnings last quarter? Cassava Sciences, Inc. (NASDAQ:SAVA) issued its earnings results on Thursday, May, 8th. The company reported ($0.48) EPS for the quarter. When did Cassava Sciences' stock split? Shares of Cassava Sciences split on the morning of Thursday, December 21st 2023. The 14-10 split was announced on Thursday, December 21st 2023. The newly created shares were issued to shareholders after the market closes on Thursday, December 21st 2023. An investor that had 100 shares of stock prior to the split would have 140 shares after the split. Who are Cassava Sciences' major shareholders? Top institutional investors of Cassava Sciences include Goldman Sachs Group Inc. (1.03%), GMT Capital Corp (0.93%), Charles Schwab Investment Management Inc. (0.75%) and Jane Street Group LLC. Insiders that own company stock include Eric Schoen and James William Kupiec. View institutional ownership trends. How do I buy shares of Cassava Sciences? Shares of SAVA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Cassava Sciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Cassava Sciences investors own include Waste Connections (WCN), Humana (HUM), American Water Works (AWK), Voyager Therapeutics (VYGR), The RMR Group (RMR), AUO (AUOTY) and DiamondRock Hospitality (DRH). Company Calendar Last Earnings5/08/2025Today5/30/2025Next Earnings (Estimated)8/14/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:SAVA CIK1069530 Webwww.cassavasciences.com Phone(512) 501-2444Fax512-501-0414Employees30Year FoundedN/APrice Target and Rating Average Stock Price Target$54.50 High Stock Price Target$107.00 Low Stock Price Target$2.00 Potential Upside/Downside+2,571.6%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($1.50) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$97.22 million Net MarginsN/A Pretax MarginN/A Return on Equity-88.05% Return on Assets-64.98% Debt Debt-to-Equity RatioN/A Current Ratio3.55 Quick Ratio3.55 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$3.26 per share Price / Book0.63Miscellaneous Outstanding Shares48,308,000Free Float43,780,000Market Cap$98.55 million OptionableOptionable Beta-2.31 10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free Report This page (NASDAQ:SAVA) was last updated on 5/30/2025 by MarketBeat.com Staff From Our PartnersBuffett’s Next Move Could Shock Wall StreetIn just a few weeks, a move decades in the making could be revealed — and when it is, it could ignite the next...Golden Portfolio | SponsoredJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredTrump Just Gave the Green Light to Rewrite Social Security?In a stunning move, President Trump has authorized an AI-led transformation of federal agencies, including Soc...Altimetry | SponsoredUrgent: Make this trade before you hit your pillow tonight… Most people waste 8 hours every night… And 227,916 hours in their lifetime… Dreaming about the life they...Timothy Sykes | SponsoredNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cassava Sciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cassava Sciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.